A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin
Interventions
DRUG

brentuximab vedotin

Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure

Trial Locations (17)

10016

NYU Clinical Cancer Center, New York

10019

Columbia University Medical Center, New York

33136

University of Miami Miller School of Medicine / Sylvester Comprehensive Cancer Center, Miami

43205

Nationwide Children's Hospital, Columbus

46237

St. Francis Medical Group Oncology & Hematology Specialists, Indianapolis

48201

Karmanos Cancer Institute / Wayne State University, Detroit

60153

Loyola University Medical Center - Cardinal Bernadin Cancer Center, Maywood

63110

Washington University School of Medicine, St Louis

75246

Charles A. Sammons Cancer Center, Dallas

75475

Hopital Saint-Louis/Service d'Hematologie, Paris

77030

MD Anderson Cancer Center /The University of Texas, Houston

80218

Colorado Blood Cancer Institute, Denver

91010

City of Hope National Medical Center, Duarte

94305

Stanford Cancer Center, Stanford

35294-3300

University of Alabama at Birmingham, Birmingham

07601

The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack

98109-1023

Seattle Cancer Care Alliance / University of Washington Medical Center, Seattle

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Seagen Inc.

INDUSTRY